← Back to feed SILVER SPRING · APR 30, 2026 · FDA
Auvelity cleared for agitation in Alzheimer’s dementia
- Sponsor
- Axsome Therapeutics
$AXSM
- Drug
- Auvelity · dextromethorphan/bupropion
- Indication
- Agitation in Alzheimer’s dementia
More on Axsome Therapeutics ↗ Google News FDA approved Auvelity for agitation associated with dementia due to Alzheimer’s disease, marking its first non-antipsychotic indication.
Read original at fda.gov ↗ Topic Alzheimer’s disease
